REACHING NEW
DESTINATIONS
A clinical-stage company focused on redefining possibilities
Pliant Therapeutics is a clinical-stage biopharmaceutical company and leader in the development of integrin-based therapeutics. Pliant is diving deep to understand and apply the role of integrins in disease, focusing on the molecular mechanisms that drive pathology to develop potentially safer and more effective therapies for patients.
Differentiated science. Meaningful impact.
Vision
A future where integrin science redefines what’s possible, offering hope to patients suffering from serious diseases.
Mission
To discover and develop differentiated integrin-based therapies that target disease at the source, creating meaningful impact on patients’ lives.
Our Team
Pliant is led by a team of world-renowned researchers and highly experienced drug developers focused on translating science into novel therapies for patients in need.
Our Responsibility
While patients are at the center of our corporate responsibility, we recognize that operating in a sustainable manner benefits all of our stakeholders, including employees, investors, the environment, communities and the patients we seek to serve. In that regard, we have undertaken various environmental, social and governance (“ESG”) initiatives, including in the areas of: environmental sustainability; access to our investigational therapies; continuing education and support; charitable contributions; and commitment to compliance and ethical business conduct.
We’re Here for Hope
General Contact
[email protected]
650-481-6770
IR & Media Contact
Christopher Keenan
Pliant Therapeutics
Vice President, Investor Relations and Corporate Communications
[email protected]
HR Contact
331 Oyster Point Blvd
South San Francisco, CA 94080